次世代シーケンサー市場：市場規模（セグメント別）、シェア、規制、償還、予測（～2033年）

次世代シーケンサーは、DNAを断片化し、それらの断片を自動化された並列的な方法で配列決定することにより、ゲノム全体を一度に配列決定することを可能にします。次世代シーケンサーは、全ゲノムシーケンス、エクソームシーケンス、トランスクリプトームシーケンス（RNAシーケンス）、多遺伝子パネルのターゲットシーケンスに使用できます。

現在では、治療方針の個別化のために多数の変異を検査することが標準となっており、標的となり得る幅広い変異について腫瘍生検を評価できる次世代シーケンサーの使用が増加しています。

当レポートは、世界の次世代シーケンサー市場について詳細に考察し、市場における競合情勢、SWOT分析、2033年までの市場予測、COVID-19の影響、地域、国別の動向などを提供しています。

目次

現在上市されている次世代シーケンサーと競合情勢

• 主要な業界動向の洞察
• 次世代シーケンサーのセグメント別総市場収益と2015年～2033年の市場展望
• 個数、平均販売価格、市場価値に関する詳細データ

世界、地域、国別の洞察

• 次世代シーケンサー市場のSWOT分析
• 次世代シーケンサー市場に関する競合力学の洞察と動向
• 国別の医療制度の概要
• 国別の償還政策
• 国別の医療技術に関する規制の状況

List of Tables

Not Applicable

List of Figures

Not Applicable

Abstract

Next Generation Sequencers Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.

The model discusses in detail the impact of COVID-19 on Next Generation Sequencers market for the year 2020 and beyond. Next Generation Sequencers allows an entire genome to be sequenced at once by fragmenting DNA and sequencing those fragments in an automated, parallel manner. Next Generation Sequencers can be used for whole-genome sequencing, exome sequencing, transcriptome sequencing (RNA sequencing), and targeted sequencing of multigene panels.

It is now standard to test for a high number of mutations to personalize treatment decisions, use of Next Generation Sequencers that can evaluate tumor biopsies for a wide range of potentially targetable mutations is increasing.

This model includes High-throughput Next Generation Sequencers, Medium-throughput Next Generation Sequencers, Low-throughput Next Generation Sequencers.

Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are:

Currently marketed Next Generation Sequencers and evolving competitive landscape:

• Insightful review of the key industry trends.
• Annualized total Next Generation Sequencers market revenue by segment and market outlooks from

2015- 2033

• Market level data on units, average selling prices and market values.

Global, Regional and Country level market specific insights:

• Qualitative market specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country specific insights on the market.
• SWOT analysis for Next Generation Sequencers market.
• Competitive dynamics insights and trends provided for Next Generation Sequencers market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

• Country specific overview of the healthcare system.
• Country specific reimbursement policies.
• Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Illumina Inc, Pacific Biosciences, Thermo Fisher Scientific Inc, Singular Genomics System Inc , and others.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -

• CMO executives who must have deep understanding of the Next Generation Sequencing (NGS) Tests market place to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to -

• Understand the impact of COVID-19 on Next Generation Sequencing (NGS) Tests market.
• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving Next Generation Sequencing (NGS) Tests market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Next Generation Sequencing (NGS) Tests market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
• Track device sales in the global and country-specific Next Generation Sequencing (NGS) Tests market from 2015-2033.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Not Applicable